Publications

Practical Ultrasound in Anesthesia for Critical Care and Pain Management

Practical Ultrasound in Anesthesia for Critical Care and Pain Management

Practical Ultrasound in Anesthesia for Critical Care and Pain Management, Hopkins PM, Bodenham AR & Reeves ST, eds. Informa Healthcare, New York, 2008

Hyperthermic and Hypermetabolic Disorders

Hyperthermic and Hypermetabolic Disorders

Hyperthermic and Hypermetabolic Disorders. Hopkins PM & Ellis FR eds. Cambridge University Press. 1996.

Foundations of Anesthesia

Foundations of Anesthesia

Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby-, London.  1999

Papers

  1. Hopkins PM, Macdonald R, Lyons G. Caesarean section at 27 weeks gestation with removal of phaeochromocytoma. British Journal of Anaesthesia 1989; 63:121-124.
  2. Urwyler A, Ellis FR, Halsall PJ, Hopkins PM. Muscle relaxation rates in individuals susceptible to malignant hyperthermia. British Journal of Anaesthesia 1990; 65: 421-423.
  3. Hopkins PM, Ellis FR, Halsall PJ. Evaluation of local anaesthetic blockade of the lateral femoral cutaneous nerve. Anaesthesia 1991; 46: 95-96.
  4. Hopkins PM, Ellis FR, Halsall PJ. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 1991; 46: 374-375.
  5. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. British Journal of Anaesthesia 1991; 66: 611-613.
  6. Stewart KG, Hopkins PM, Dean SG. Comparison of high and low doses of suxamethonium. Anaesthesia 1991; 46: 833-836.
  7. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991; 338: 1491-1492.
  8. Ball SP, Dorkins HR, Ellis FR, Hall JL, Halsall PJ, Hopkins PM, Mueller R, Stewart AD. Segregation analysis of chromosome 19 markers in malignant hyperthermia. British Journal of Anaesthesia 1993;70:70-75.
  9. Ellis FR, Halsall PJ, Hopkins PM. Is the K-type halothane/caffeine responder susceptible to malignant hyperthermia? British Journal of Anaesthesia 1992;69:468-470.
  10. Bellamy MC, Hopkins PM, Halsall PJ, Ellis FR. Study into the incidence of methaemoglobinaemia after prilocaine 3:1 block. Anaesthesia 1992;47:1084-1085.
  11. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with halothane, caffeine and ryanodine in patients with malignant hyperthermia and other neuromuscular disorders. British Journal of Anaesthesia 1993;70:397-401.
  12. Burns AP, Hall G., Pusey CD, Hopkins PM.  Rhabdomyolysis and acute renal failure in unsuspected malignant hyperpyrexia.  Quaterly Journal of Medicine 1993; 86: 431-434.
  13. Ahmed IA, Hopkins PM, Winlow W. Caffeine and ryanodine differentially modify a calcium-dependent component of soma action potentials in identified molluscan (Lymnaea stagnalis) neurones in situ. Comparative Biochemistry and Physiology 1993; 105C: 363-372.
  14. Iles D, Segers B, Sengers R, Monsieurs K, Heytens L,  Halsall PJ, Hopkins PM, Ellis FR, Hall-Curran JL, Stewart AD, Wieringa B. Genetic mapping of the b and g subunits of the human skeletal muscle voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Human Molecular Genetics 1993; 2: 863-868.
  15. Hall-Curran JL, Stewart AD, Ball SP, Halsall PJ, Hopkins PM, Ellis FR. No C1840 to T mutation in RYR1 in malignant hyperthermia.  Human Mutation 1993; 2: 330.
  16. Hopkins PM, Halsall PJ, Ellis FR.  The effects of benzamil on in vitro contracture responses of human skeletal muscle to halothane.  General Pharmacology 1994; 25: 23-29.
  17. Michels AMJ, Lyons G, Hopkins PM.  Lignocaine test dose to detect intravenous injection.  Anaesthesia 1995; 50: 211-213.
  18. Winlow W, Hopkins PM, Moghadam HF, Ahmed IA, Yar T.  Multiple cellular and subcellular actions of general anaesthetics on cultured molluscan neurones.  Acta Biologica Hungarica 1995; 46: 381-393.
  19. Hopkins PM.  Human recombinant TNFα affects rat diaphragm muscle in vitro.  Intensive Care Medicine 1996; 22: 359-362.
  20. Simpson KH, Murphy PG, Hopkins PM, Batchelor AG.  Prediction of outcomes in 150 patients having microvascular free tissue transfer to the head and neck.  British Journal of Plastic Surgery 1996; 49: 267-273.
  21. Halsall PJ, Bridges LR, Ellis FR, Hopkins PM.  Central core disease and malignant hyperthermia are not always associated.  Journal of Neurology, Neurosurgery & Psychiatry1996; 61:119-21.
  22. Laurence AS, Vanner GK, Collins W, Hopkins PM.  Serum and urinary myoglobin following an aborted malignant hyperthermia reaction.  Anaesthesia 1996; 51: 958-960.
  23. Ahmed IA, Hopkins PM, Winlow W.  Low concentrations of caffeine raise intracellular calcium concentration only in the presence of extracellular calcium in cultured molluscan neurones.  General Pharmacology.  1997; 28: 245-50.
  24. Hopkins PM, Halsall PJ, Ellis FR, Stewart AD.  An analysis of the predictive probability of the in vitro contracture test for determining malignant hyperthermia susceptibility.  Anesthesia and Analgesia  1997; 84: 648-656.
  25. Adeokun AM, West SP, Ellis FR, Halsall PJ, Hopkins PM, Foroughmand A, Iles D, Stewart AD, Curran JL.  The G1021A substitution in the RYR1 gene does not always cosegregate with malignant hyperthermia susceptibility in a British pedigree.  American Journal of Human Genetics 1997; 60: 833-841.
  26. Robinson R, Monnier N, Wolz W, Jung M, Reis A, Nuernberg G, Curran JL, Monsieurs K, Stieglitz P, Heytens L, Fricker R, van Broeckhoven C, Deufel T, Hopkins PM, Lunardi J, Mueller C.  A genome-wide search for susceptibility loci in two European malignant hyperthermia pedigrees. Human Molecular Genetics 1997; 6: 953-961.
  27. Robinson R,. Curran JL,. Hall WJ,. Halsall PJ, Hopkins PM,.  Stewart AD,. Markham AF, West SP, Ellis FR.  Genetic heterogeneity and homog analysis in British malignant hyperthermia families. Journal of Medical Genetics 1998; 35:196-201
  28. Majumder S, Hopkins PM.  Bilateral lingual nerve injury following the use of the laryngeal mask airway.  Anaesthesia 1998; 53: 184-186.
  29. Hindle AT, Hopkins PM. 5-Hydroxytryptamine causes depression in the partially curarised rat phrenic nerve diaphragm preparation. British Journal of Anaesthesia. 1998; 80: 90-91.
  30. Hopkins PM, Hartung E, Wappler F, European Malignant Hyperthermia Group.  Multi-centre evaluation of ryanodine contracture testing in malignant hyperthermia.  British Journal of Anaesthesia 1998; 80: 389-394.
  31. Hindle AT, Hopkins PM. 5-Hydroxytryptamine potentiates post-tetanic contractile responses in the rat phrenic nerve diaphragm preparation.  European Journal of Anaesthesiology 1998; 15: 216-223.
  32. Ramirez JA, Cheetham ED, Laurence AS, Hopkins PM.  Suxamethonium, masseter spasm and later malignant hyperthermia.  Anaesthesia 1998; 53: 1111-1116.
  33. Harrison SM, Robinson M, Davies LA, Hopkins PM, Boyett MR.  Mechanisms underlying the inotropic action of the general anaesthetic halothane on intact rat ventricular myocytes.  British Journal of Anaesthesia 1999; 82: 609-621.
  34. Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Iles DE, Markham AF, McCall SH, Robinson RL, West SP, Bridges LR , Ellis FR.  Segregation of malignant hyperthermia, central core disease and chromosome 19 markers.  British Journal of Anaesthesia 1999; 83: 217-222..
  35. Davies LA, Hamilton DL, Hopkins PM, Boyett MR, Harrison SM.  Concentration-dependent inotropic effects of halothane, isoflurane and sevoflurane on ventricular cells. British Journal of Anaesthesia 1999; 82: 723-730.
  36. Janzen PRM, Hall WJ, Hopkins PM. Setting targets for sedation using target-controlled propofol infusion. Anaesthesia 2000; 55: 666-669.
  37. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw M-A.  Multiple interacting gene products may influence susceptibility to malignant hyperthermia.  Annals of Human Genetics 2000; 64: 307-320.
  38. Hamilton DL, Boyett MR, Harrison SM, Davies LA, Hopkins PM. Concentration-dependent effects of propofol on rat ventricular myocytes. Anesthesia & Analgesia 2000; 91: 276-282.
  39. O’Riordan JA, Hopkins PM, Ravenscroft A, Stevens JD.  Postoperative urinary retention and the influence of the mode of analgesia in patients undergoing lower limb joint replacements.  European Journal of Anaesthesiology 2000; 17: 431-435.
  40. Davies LA, Gibson CN, Boyett MR, Hopkins PM, Harrison SM. Effects of isoflurane, sevoflurane and halothane on myofilament Ca2+ sensitivity and sarcoplasmic reticulum Ca2+ release in rat ventricular myocytes. Anesthesiology 2000; 93: 1034-1044.
  41. Davies LA, Hopkins PM, Boyett MR, Harrison SM. Effects of halothane on the transient outward K+ current in rat ventricular myocytes. British Journal of Pharmacology 2000; 131: 223-230
  42. Janzen PRM, Vipond AJ, Bush DJ, Hopkins PM. A comparison of 1% prilocaine with 0.5% ropivacaine for outpatient-based surgery under axillary brachial plexus block. Anesthesia & Analgesia 2001; 93: 187-191
  43. Rithalia A, Gibson CN, Hopkins PM, Harrison SM. Halothane inhibits contraction and action potential duration to a greater extent in subendocardial than subepicardial myocytes from the rat left ventricle. Anesthesiology. 2001; 95: 1213-1219.
  44. Brooks C, Robinson RL, Halsall PJ, Hopkins PM. No evidence of mutations in the CACNA1S gene in the UK malignant hyperthermia population. British Journal of Anaesthesia 2002; 88: 587-589.
  45. Claxton BA, Cross MH, Hopkins PM. No response to trigger agents in a malignant hyperthermia-susceptible patient. British Journal of Anaesthesia 2002; 88: 870-873.
  46. Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, Shaw M-A, Hopkins PM. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Human Mutation 2002;20:88-97
  47. Duke AM, Hopkins PM, Steele DS. Effects of Mg2+ and SR luminal Ca2+ on caffeine-induced Ca2+ release in skeletal muscle from humans susceptible to malignant hyperthermia. Journal of Physiology 2002; 544.1: 85–95
  48. Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Frocker R, Halsall PJ, Hartung E, Heffron JJA, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am Esch J. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. European Journal of Anaesthesiology 2003; 20: 528-36
  49. Robinson R, Hopkins PM, Carsana A , Gilly H, Halsall PJ, Heytens L, Islander G, Jurkat-Rott K, Mueller CR, Shaw M-A. Several interacting genes influence the malignant hyperthermia phenotype. Human Genetics 2003; 112: 217-218
  50. Robinson RL, Anetseder MJ, Brancadoro V, van Broekhaven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klingler W, Kozak-Ribbens G, Krivosic R, Monnier N, Nivoche Y, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? European Journal of Human Genetics 2003;11:342-8.
  51. Duke AM, Hopkins PM, Steele DS. Mg2+-dependence of halothane-induced Ca2+ release from the sarcoplasmic reticulum in skeletal muscle. Journal of Physiology 2003; 551: 447–454.
  52. Rithalia A, Hopkins PM, Harrison SM. Effects of halothane on action potential configuration in sub-endocardial and sub-epicardial myocytes from normotensive and hypertensive rat left ventricle. British Journal of Anaesthesia 2003; 90: 501-503.
  53. Johi RR, Mills R, Halsall PJ, Hopkins PM. Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy. British Journal of Anaesthesia 2003; 91:744-6 
  54. Graham MD, Hopkins PM, Harrison SM. Effects of alfentanil on cytosolic calcium and contraction in rat ventricular myocytes. Anesthesia and Analgesia 2004;98: 1013-1016
  55. Shepherd S, Ellis R, Halsall J, Hopkins P, Robinson R. RYR1 mutations in UK central core diseases patients: more than just the C-terminal transmembrane region of the RYR1 gene. Journal of Medical Genetics 2004;41:e33
  56. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle & Nerve. 2004;30:114-7.
  57. Rithalia A, Hopkins PM, Harrison SM. Effects of halothane, isoflurane and sevoflurane on Ca2+ current and transient outward K+ current in sub-endocardial and sub-epicardial myocytes from the rat left ventricle. Anesthesia and Analgesia 2004;99: 1615-1622
  58. Duke AM, Hopkins PM, Halsall PJ, Steele DS. Mg2+-dependence of halothane-induced Ca2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia. Anesthesiology 2004; 101: 1339-1346
  59. Graham MD, Bru-Mercier G, Hopkins PM, Harrison SM. Transient and sustained changes in myofilament sensitivity to Ca2+ contribute to the inotropic effects of sevoflurane in rat ventricle. British Journal of Anaesthesia 2005;94:279-86.
  60. Bru-Mercier G, Hopkins PM, Harrison SM.  Halothane and sevoflurane inhibit Na/Ca exchange current in rat ventricular myocytes. British Journal of Anaesthesia 2005;95:305-9
  61. Robinson RL, Carpenter D, Shaw M-A, Halsall PJ, Hopkins PM. Mutations in ryr1 in malignant hyperthermia and central core disease. Human Mutation 2006; 27: 977-989
  62. Graham MD, Hopkins PM, Harrison SM. Antagonistic  actions of halothane and sevoflurane on spontaneous Ca2+ release in rat ventricular myocytes. Anesthesiology 2006; 105: 58-64
  63. Duke AM, Hopkins PM, Halsall PJ, Steele DS. Mg2+-dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. British Journal of Anaesthesia 2006; 97: 320-8
  64. Lahoud GY, Hopkins PM. Balanced conscious sedation with intravenous induction and inhalational maintenance for patients requiring endoscopic and/or surgical procedures. European Journal of Anaesthesiology 2007;24:116-21
  65. Duncan DJ, Hopkins PM, Harrison SM. Negative inotropic effects of tumour necrosis factor-α and interleukin-1β are ameliorated by alfentanil in rat ventricular myocytes. British Journal of Pharmacology 2007; 150: 720-6
  66. Bahnasi YM, Wright HM, Milligan CJ, Dedman AM, Zeng F, Hopkins PM, Bateson AN, Beech DJ. Modulation of TRPC5 cation channel by halothane, chloroform and propofol. British Journal of Pharmacology 2008; 153: 1505-12
  67. Carpenter D, Morris A, Robinson RL, Booms P, Iles D, Halsall PJ, Steele D, Hopkins PM, Shaw MA. Analysis of RYR1 haplotype profile in patients with malignant hyperthermia. Annals of Human Genetics 2009;73:10-8.
  68. Robinson RL, Carpenter D, Halsall PJ, Iles DE, Booms, P, Steele D, Hopkins PM, Shaw M-A. Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility. British Journal of Anaesthesia 2009; 103: 220-5
  69. Carpenter D, Ismail A, Robinson RL, Ringrose C, Booms P, Iles D, Halsall PJ, Steele D, Shaw M-A, Hopkins PM. A RYR1 mutation associated with recessive congenital myopathy and dominant malignant hyperthermia in Asian families. Muscle & Nerve 2009; 40: 663-669
  70. Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles D, Halsall PJ, Steele D, Shaw M-A, Hopkins PM. Genetic variation in RYR1 and malignant hyperthermia phenotypes. British Journal of Anaesthesia 2009; 103: 538-548
  71. Carpenter D, Ringrose C, Leo V, Morris A, Robinson R, Halsall PJ, Hopkins PM, Shaw M-A. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Medical Genetics 2009; 10:104.
  72. Gupta PK, Pace NL, Hopkins PM. Effect of body mass index on the ED50 volume of bupivacaine 0.5% for supraclavicular brachial plexus block.
    British Journal of Anaesthesia 2010; 104: 490-5
  73. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-α  and IL-1β  increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 2010; 47: 378–86
  74. Duke AM, Hopkins PM, Calaghan SC, Halsall PJ, Steele DS. Store operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle. Journal of Biological Chemistry 2010; 285: 25645-53
  75. Saleh D, Nikkah D, Bhat W, Hopkins P. A retrospective survey of brachial plexus blockade in pediatric hand trauma patients. Paediatric Anaesthesia 2011;21:1166-8
  76. Eltit JM, Bannister RA, Moua O,  Altamirano F, Hopkins PM, Pessah IN, Molinski TF, López JR, Beam KG, Allen PD. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. Proceedings of the National Academy of Science 2012; 109: 7923–8
  77. Kant A, Gupta PK, Zohar S, Chevret S, Hopkins PM. Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. Anesthesiology 2013. 119:29-35
  78. Gupta PK, Zohar S, Chevret S, Hopkins PM. What is the ED95 of prilocaine for femoral nerve block using ultrasound? British Journal of Anaesthesia 2013; 110:831-6
  79. Gupta PK, Hopkins PM. Effect of concentration of local anaesthetic solution on the ED50 of bupivacaine for supraclavicular brachial plexus block. British Journal of Anaesthesia 2013; 111:293-6
  80. Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G, Quinlivan R, Snoeck M, Norwood F, Radunovic A, Straub V, Roberts M, Vrancken AF, van der Pol L, de Coo RF, Manzur AY, Yau S, Abbs S, King A, Lammens M, Hopkins, PM, Mohammed S, Treves S, Muntoni F, Wraige E, Davis MR, van Engelen B, Jungbluth H. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders 2013; 23:540-8.
  81. Kim J, Jarvik GP, Browning BL, Rajagopalan R, Gordon AS, Rieder MJ, Robertson PD, Nickerson DA, Fisher NA, Hopkins PM. Exome sequencing reveals novel rare variants in ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology 2013; 119:  1054-65
  82. Forrest KM, Foulds N, Millar JS, Sutherland PD, Pappachan VJ, Holden S, Mein R, Hopkins PM, Jungbluth H.  RYR1-related malignant hyperthermia with marked cerebellar involvement – A paradigm of heat-induced CNS injury? Neuromuscular Disorders. 2015; 25: 138-40
  83. Savic L, Jackson R, Hammond-Jones A-M, Yusaf M, Kaura V, Howell SJ, Savic S, Hopkins PM; Anaesthetic Audit and Research Matrix of Yorkshire. Incidence of Suspected Perioperative Anaphylaxis – A Multi-Center Snapshot Study. Journal of Allergy and Clinical Immunology: In Practice 2015: 3; 454-5.e1
  84. Fiszer D, Shaw M-A, Fisher NA, Carr IM, Gupta PK , Watkins EJ, Roiz de Sa D, Kim JH, Hopkins PM. Next generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness. Anesthesiology 2015: 122;1033-46
  85. Savic L, Garcez T, Hopkins PM, Harper NJN, Savic S. Teicoplanin allergy – an emerging problem in the anaesthetic allergy clinic. British Journal of Anaesthesia 2015;115:595-600
  86. Logan CV, Cossins J, Rodriguez Cruz PM, Parry DA, Maxwell S, Martinez PM, Riepsaamw J, Abdelhamed ZA, Lake AV, Moran M, Robb S, Chw G, Sewry C, Hopkins PM, Sheridan E, Jayawant S, Palace J, Johnson CA, Beeson D. Congenital myasthenic syndrome type 19 is caused by mutations in COL13A1, encoding the atypical non-fibrillar collagen type XIII a1 chain. American Journal of Human Genetics 2015; 7:878-85

 Editorials and review articles

  1. Hopkins PM, Halsall PJ, Ellis FR. Diagnosing malignant hyperthermia susceptibility.  Anaesthesia 1994; 49: 373-375.
  2. Hopkins PM. Use of suxamethonium in children.  British Journal of Anaesthesia 1995; 75: 675-677.
  3. Hopkins PM. A shame about the patient?. British Journal of Anaesthesia 2000; 84: 1-2.
  4. Hopkins PM, Hunter JM. Endocrine and metabolic disorders in anaesthesia and intensive care. British Journal of Anaesthesia. 2000; 85: 1-2.
  5. Robinson RL, Hopkins PM. A breakthrough in the genetic diagnosis of malignant hyperthermia. British Journal of Anaesthesia 2001; 86: 166-168
  6. Hopkins PM. Ultrasound guidance as a gold standard in regional anaesthesia. British Journal of Anaesthesia 2007 98: 299-301
  7. Hopkins PM. Is there a link between malignant hyperthermia and exertional heat illness? British Journal of Sports Medicine 2007; 41: 283-4
  8. Hopkins PM. Recrudescence of malignant hyperthermia. Anesthesiology 2007; 106:893-4
  9. Hopkins PM, Hardman JG. Advances in pharmacology and therapeutics. British Journal of Anaesthesia 2009; 103: 1-2
  10. Hopkins PM. Anaesthesia and the sex-linked dystrophies: between a rock and a hard place. British Journal of Anaesthesia 2010;104:397-400
  11. Gupta PK, Hopkins PM. Malignant hyperthermia in India. Anaesthesia 2010; 65: 1063-5
  12. Gupta PK, Hopkins PM. Regional anaesthesia for all? British Journal of Anaesthesia 2012; 109:7-9.
  13. Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. Anaesth Intensive Care 2014: 7-9
  14. Columb MO, Hopkins PM. Programmes, guidelines and protocols – the antithesis of precision medicine? British Journal of Anaesthesia 2015; 115: 485-7
  15. Hopkins PM, Ellis FR. Malignant Hyperthermia. Current Opinion in Anaesthesiology 1992;5: 415-419.
  16. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. British Journal of Anaesthesia 2000; 85: 118-128.
  17. H. Grogan and P. M. Hopkins. Heat stroke: implications for critical care and anaesthesia. British Journal of Anaesthesia 2002 88: 700-707
  18. PJ Halsall, PM Hopkins. Malignant hyperthermia. BJA CEPD Reviews 2003; 3:5-9
  19. Hopkins PM. Nitrous oxide: a unique drug of continuing importance for anaesthesia. Best Practice & Research Clinical Anaesthesiology 2005; 19: 381-9
  20. Hopkins PM. Skeletal muscle physiology. Continuing Education in Anaesthesia, Critical Care and Pain 2006; 6:1-6.
  21. Hopkins PM. Malignant hyperthermia. Current Anaesthesia and Critical Care 2008; 19: 22–33
  22. Hopkins PM. Malignant hyperthermia. Anaesthesia and Intensive Care Medicine 2008; 9:244-6
  23. Harper NJ, Dixon T, Dugué P, Edgar DM, Fay A, Gooi HC, Herriot R, Hopkins P, Hunter JM, Mirakian R, Pumphrey RS, Seneviratne SL, Walls AF, Williams P, Wildsmith JA, Wood P, Nasser AS, Powell RK, Mirakhur R, Soar J. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia. 2009;64:199-211
  24. Searle R, Hopkins PM. Pharmacogenomic variability and anaesthesia. British Journal of Anaesthesia 2009; 103: 14-25
  25. Klingler, W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM. Core myopathies and the risk of malignant hyperthermia. Anesthesia and Analgesia 2009; 109: 1167-73
  26. Hopkins PM. Malignant hyperthermia. Anaesthesia and Intensive Care Medicine 2011; 12:263-5
  27. Hopkins PM. Malignant hyperthermia – pharmacology of triggering. British Journal of Anaesthesia 2011; 107:48-56
  28. Kessler J, Marhofer P, Hopkins PM, Hollmann MW. Peripheral regional anaesthesia and outcome: Lessons learned from the last ten years. British Journal of Anaesthesia 2015: 114;728-45
  29. Hopkins PM, Rüffert H, Snoeck MM,  Girard T, Glahn KPE, Ellis FR, Müller CR, Urwyler A, European Malignant Hyperthermia Group. The European Malignant Hyperthermia Group guidelines for the investigation of malignant hyperthermia susceptibility. British Journal of Anaesthesia 2015: 115: 531-9
  30. Hopkins PM. Does regional anaesthesia improve outcome? British Journal of Anaesthesia 2015; 115 Suppl 2:ii26-ii33

Books and Chapters in books

  1. Hopkins PM, Ellis FR. Inherited disease affecting anaesthesia. In: Healy TEJ, Cohen PJ, eds. A Practice of Anaesthesia, 6th edition. London: Edward Arnold, 1995: 938-952.
  2. Hopkins PM, Ellis FR.  Neuromuscular pathology and malignant hyperthermia,  In: Prys-Roberts C, Brown BR, eds.  International Practice of Anaesthesia, Butterworth Heinemann, Oxford. 1996: Vol. 1:1/92/1-1/92/7.
  3. Hopkins PM, Ellis FR.  Electromyography and the measurement of muscle function.  In: Prys-Roberts C, Brown BR, eds.International Practice of Anaesthesia, Butterworth Heinemann, Oxford; 1996 vol 2:2/161/1-2/161/6.
  4. Hopkins PM, Ellis FR, Halsall PJ.  Investigation of exertional heat stroke, III: in vitro contracture tests. In Hopkins PM & Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge University Press.  1996; 93-101.
  5. Hopkins PM.  Future research into exertional heat stroke. In Hopkins PM & Ellis FR, eds. Hyperthermic and Hypermetabolic Disorders. Cambridge University Press.  1996; 102-104.
  6. Hopkins PM.  Malignant hyperthermia: clinical presentation. In Goldstone J & Pollard B, eds.  Handbook of Clinical Anaesthesia.  Churchill Livingstone, London. 1996: 644-645.
  7. Hopkins PM.  Masseter muscle spasm. In Goldstone J & Pollard B, eds.  Handbook of Clinical Anaesthesia.  Churchill Livingstone, London.  1996: 646-647.
  8. Winlow W, Hopkins PM, Moghadam HF, Ahmed IA, Yar T.  Neurobiology of Invertebrates.  Handbook of Akademiai Kiado, Budapest, 1996: 381-393.
  9. Hopkins PM, Winlow W.  Mechanisms of anesthesia. In: Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby, London.  1999: 233-240
  10. Hopkins PM.  Voluntary motor systems – skeletal muscle. In: Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby, London.  1999: 319-330
  11. O’Beirne HA, Hopkins PM.  Smooth muscle.  In: Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby, London.  1999:353 – 360
  12. Enright SM, Hopkins PM.  Acid-base homeostasis.  In: Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby, London.  1999: 583-592.
  13. Hopkins PM. Future research strategies for prevention and treatment of PONV. In: Effective management of post-operative nausea and vomiting, L Strunin, DJ Rowbotham & A Miles , eds. Aesculapius Medical Press, London. 1999: 125-134.
  14. Hopkins PM. Ryanodine contracture tests. In; Malignant hyperthermia, J Schulte am Esch, J Scholz & F Wappler, eds. Pabst Science Publishers, Lengerich. 2000: 262-270.
  15. Hopkins PM, Bush DJ. Anesthesiology and pain control. In: Surgery, JD Corson & RCN Williamson, eds. Mosby, London. 2001: 1.15.1-1.15.12.
  16. Clarke PR, Hopkins PM. Endocrine Physiology. In: Textbook of Anaesthesia, 4th Edition. Aitkenhead A, Rowbotham DJ, Smith G, eds. Churchill Livingstone, London. 2001: 309-322.
  17. Halsall PJ, Hopkins PM. Inherited disease and anesthesia. In: Healy TEJ, Cohen PJ, eds. A Practice of Anesthesia, 7th edition. Arnold, London: 2003: 377-390.
  18. Hopkins PM. Future research strategies for prevention and treatment of post-operative nausea and vomiting. In: Effective prevention and management of post-operative nausea and vomiting, 2nd ed, L Strunin, DJ Rowbotham & A Miles , eds. Aesculapius Medical Press, London. 2003: 161-172
  19. Hopkins PM.  Malignant hyperthermia: clinical presentation. In Pollard BJ, ed.  Handbook of Clinical Anaesthesia, 2nd ed.  Churchill Livingstone, London. 2004: 764-766.
  20. Hopkins PM.  Masseter muscle spasm. In Pollard BJ, ed.  Handbook of Clinical Anaesthesia, 2nd ed.  Churchill Livingstone, London.  2004: 767-768.
  21. Hopkins PM.  Adverse drug reactions. In: Foundations of Anesthesia: Basic Sciences for Clinical Practice, 2nd edition, HC Hemmings Jr & Hopkins PM, eds.  Mosby-Elsevier, London, 2005: 129-135
  22. Hopkins PM.  Voluntary motor systems – skeletal muscle, reflexes and control of movement. In: Foundations of Anesthesia: Basic Sciences for Clinical Practice, 2nd edition, HC Hemmings Jr & Hopkins PM, eds.  Mosby-Elsevier, London, 2005: 421-433
  23. Gupta PK, Hopkins PM. Ultrasound–guided peripheral and regional nerve block. In: Practical Ultrasound in Anesthesia for Critical Care and Pain Management, Hopkins PM, Bodenham AR & Reeves ST, eds. Informa Healthcare, New York, 2008:71-84
  24. Holbrook SP, Hopkins PM. Temperature. In: Consent, benefit and risk in anaesthetic practice, Hardman JG, Moppett IK & Aitkenhead AR, eds. Oxford University Press, Oxford, 2009:285-308.
  25. Hopkins PM.  Malignant hyperthermia: clinical presentation. In Pollard BJ, ed.  Handbook of Clinical Anaesthesia, 3rd ed.  Hodder Arnold, London. 2011: 770-1.
  26. Hopkins PM.  Masseter muscle spasm. In Pollard BJ, ed.  Handbook of Clinical Anaesthesia, 3rd ed.  Hodder Arnold, London. 2011: 772-3
  27. Kant A, Hopkins PM. Adverse drug reactions. In Pharmacology and physiology for anesthesia: foundations and clinical application, Hemmings HC Jr & Egan TD eds. Elsevier Saunders, Philadelphia. 2013: 86-99
  28. Hopkins PM, Urwyler A. Malignant hyperthermia. In: Landmark Papers in Anaesthesia, Webster NR & Galley HF, eds. Oxford University Press, Oxford. 2013: 445-74
  29. Books
  30. Hyperthermic and Hypermetabolic Disorders. Hopkins PM & Ellis FR eds. Cambridge University Press. 1996.
  31. Foundations of Anesthesia: Basic and Applied Sciences, HC Hemmings Jr & Hopkins PM, eds.  Mosby-, London.  1999
  32. Foundations of Anesthesia: Basic Sciences for Clinical Practice, 2nd edition, HC Hemmings Jr & Hopkins PM, eds.  Mosby-Elsevier, London, 2005.
  33. Practical Ultrasound in Anesthesia for Critical Care and Pain Management, Hopkins PM, Bodenham AR & Reeves ST, eds. Informa Healthcare, New York, 2008
  34. Oxford Textbook of Anaesthesia, Hardman JG, Struys MMF & Hopkins PM, eds. Oxford University Press, Oxford. In press.

A further 121 published contributions in the form of correspondence and conference abstracts.